Fibrates and cholestasis

Cited by (318)

Items 301–318 of 318

1. Additional file 1 of Engineered FGF19ΔKLB protects against intrahepatic cholestatic liver injury in ANIT-induced and Mdr2-/- mice model
   Shi, Lu, Zhao, Tiantian, Lei Huang, Xiaomin Pan, Tianzhen Wu, Xin Feng, Taoli Chen, Jiamin Wu, Jianlou Niu · 2024 · Figshare
2. Additional file 2 of BM-MSCs overexpressing the Numb enhance the therapeutic effect on cholestatic liver fibrosis by inhibiting the ductular reaction
   Yannan Xu, Xu, Wen, Zhang, Xu, Danyang Wang, Zheng, Xin-rui, Wei Liu, Jiamei Chen, Gaofeng Chen, Ping Liu, Ping Liu et al. · 2024 · Figshare
3. Additional file 1 of BM-MSCs overexpressing the Numb enhance the therapeutic effect on cholestatic liver fibrosis by inhibiting the ductular reaction
   Yannan Xu, Xu, Wen, Zhang, Xu, Danyang Wang, Zheng, Xin-rui, Wei Liu, Jiamei Chen, Gaofeng Chen, Ping Liu, Ping Liu et al. · 2024 · Figshare
4. Die primär sklerosierende Cholangitis als cholestatische Lebererkrankung und Modellerkrankung einer gestörten Darm-Leber-Achse
   Philipp Dignus, Jörg Albert, Jan Georg Hengstler, Christian Trautwein · 2026 · Die Gastroenterologie
5. Metabolic Factors Affecting Liver Regeneration
   M. Ammann, Patrick P. Starlinger · 2026 · Springer eBooks
6. Pharmacological strategies targeting hepatocyte-mediated crosstalk in liver fibrosis.
   Yue Zhang, Meng-Guang Wei, Xin-Yue Zhou, Lian-Wen Qi, Qun Liu · 2026 · TIPS - Trends in Pharmacological Sciences
7. Sabinineoside B alleviates metabolic dysfunction-associated steatotic liver disease by targeting PPAR α
   Yan Feng, Renhao Chen, Yiming Li, Yilei Wang, Yuwei Wang, Zhiqiang Li, Daofeng Chen, Qi Wang, Zhifeng Li · 2026 · Communications Biology
8. Calculus Bovis ameliorates primary sclerosing cholangitis via a dual-pronged mechanism restoring bile acid and lipid homeostasis in the gut-liver axis
   Xuepeng Gong, Yufei Chen, Tinghui Zhao, Ninghong Li, Guangjie Yang, Lihui Qiu, Zaoqin Yu, Dong Liu, Dong Xiang · 2026 · Chinese Medicine
9. Hepatic Bmal1 alleviates cholestasis in female mice through direct regulation of SULT2A1
   Yifei Xiao, Jiatian He, Yi Zheng, Xinyu Zhang, J Li, Meng Jin, Chen M, Yushan Wu, X D Liu, Haiman Xu et al. · 2026 · Biochemical Pharmacology
10. Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Chronic Liver Diseases: Translating Mechanistic Insights into Clinical Practice and Future Perspectives
    Mario Romeo, Claudio Basile, Andrea Imperatore, Giambattista Mozzi, Fiammetta Di Nardo, Carmine Napolitano, Paolo Vaia, Luigi Di Puorto, Mattia Indipendente, Marcello Dallio et al. · 2026 · Cells
11. Targeting PPAR-Regulated Pathways to Treat Cholestatic Liver Diseases: Novel Applications of Liquid Biopsies
    Colleen M. Hayes, Daniella R. Cross, Brahim Achour, Nisanne S. Ghonem · 2026 · Cells
12. Real-world treatment patterns and clinical outcomes of patients with primary biliary cholangitis in the United States
    Nisreen Shamseddine, Hongbo Yang, Su Zhang, Dongni Ye, Shravanthi M. Seshasayee, Jingyi Chen, Sonal Rajesh Kumar, Kris V. Kowdley · 2026 · Journal of Comparative Effectiveness Research
13. Elafibranor in selected patients with primary biliary cholangitis and cirrhosis: An exploratory real-world cohort study
    Nargiz Nuruzade, Ulya Oruc, Georgios Konstantis, Moritz Passenberg, Arash Dooghaie Moghadam, Jan Best, Claudia Veltkamp, Florian Seltsam, Hartmut Schmidt, Katharina Willuweit et al. · 2026 · Therapeutic Advances in Gastroenterology
14. Cynaroside Attenuates Ethinylestradiol-Induced Cholestatic Liver Injury by Modulating the FXR/BSEP/CYP7A1/SHP Axis
    Amany M. Hamed, Doha M. Al-Nouri, Nadia S. Mahrous, Asmaa Sabry Bassit, Azza Abouelella, Asmaa Hassan, Gehad Mokhtar, Ghada M. Ahmad, Ahmed Osman, Ahmed Hamed et al. · 2026 · International Journal of Molecular Sciences
15. Integrative metabolomics and malonyl-proteomics reveal the crosstalk between metabolic reprogramming and lysine malonylation in liver fibrosis
    Yun Wang, Huiran Zheng, Ran Chen, Yihang Song, Dongdong Song, Ranran Sun, Zujiang Yu, Liwen Liu · 2026 · Journal of Physiology and Biochemistry
16. Lactobacillus helveticus R0052 Ameliorates Cholestasis with FXR-Related Pathways and Modulation of Gut Microbiota
    Xueyang Chen, Li Jiang, Ailing Li, Jian Shen · 2026 · Microorganisms
17. BindingDB Entry 50006693: Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis.
    BindingDB · 2021 · UC San Diego
18. Hepatolithiasis: Indian Scenario
    Raman Kumar Gupta, Ravish Sanghi Raju · 2026 · GI surgery annual